Clinical utility of genetic risk testing in primary care: The example of Type 2 diabetes

Allison Vorderstrasse, Alex Cho, Corrine I. Voils, Lori A. Orlando, Geoffrey S. Ginsburg

Research output: Contribution to journalReview article

Abstract

Genetic advances in Type 2 diabetes (T2D) have led to the discovery and validation of multiple markers for this complex disease. Despite low predictive value of current T2D markers beyond clinical risk factors and family history, researchers are exploring the clinical utility and outcomes of implementation in practice, and testing is available via direct-to-consumer markets. Clinical utility research demonstrates high hypothetical utility to patients for motivating behavior change and potentially reducing risk. However, trials to date have not demonstrated improvements in behavioral and clinical outcomes over and above counseling based on traditional risk factors. Ongoing research in T2D genetics and associated risk-prediction models is necessary to refine genetic risk pathways, algorithms for risk prediction and use of this information in clinical care. Further research is also needed to explore care models and support interventions that address the needs of personalized risk information and sustainable preventive behaviors to reduce the rising prevalence of T2D.

Original languageEnglish (US)
Pages (from-to)549-563
Number of pages15
JournalPersonalized Medicine
Volume10
Issue number6
DOIs
StatePublished - Aug 2013

Fingerprint

Genetic Testing
Type 2 Diabetes Mellitus
Primary Health Care
Research
Counseling
Biomarkers
Research Personnel

Keywords

  • clinical utility
  • genetic testing
  • personal utility
  • Type 2 diabetes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Clinical utility of genetic risk testing in primary care : The example of Type 2 diabetes. / Vorderstrasse, Allison; Cho, Alex; Voils, Corrine I.; Orlando, Lori A.; Ginsburg, Geoffrey S.

In: Personalized Medicine, Vol. 10, No. 6, 08.2013, p. 549-563.

Research output: Contribution to journalReview article

Vorderstrasse, Allison ; Cho, Alex ; Voils, Corrine I. ; Orlando, Lori A. ; Ginsburg, Geoffrey S. / Clinical utility of genetic risk testing in primary care : The example of Type 2 diabetes. In: Personalized Medicine. 2013 ; Vol. 10, No. 6. pp. 549-563.
@article{71804b38a0b54bb08b6da6a60b0ece44,
title = "Clinical utility of genetic risk testing in primary care: The example of Type 2 diabetes",
abstract = "Genetic advances in Type 2 diabetes (T2D) have led to the discovery and validation of multiple markers for this complex disease. Despite low predictive value of current T2D markers beyond clinical risk factors and family history, researchers are exploring the clinical utility and outcomes of implementation in practice, and testing is available via direct-to-consumer markets. Clinical utility research demonstrates high hypothetical utility to patients for motivating behavior change and potentially reducing risk. However, trials to date have not demonstrated improvements in behavioral and clinical outcomes over and above counseling based on traditional risk factors. Ongoing research in T2D genetics and associated risk-prediction models is necessary to refine genetic risk pathways, algorithms for risk prediction and use of this information in clinical care. Further research is also needed to explore care models and support interventions that address the needs of personalized risk information and sustainable preventive behaviors to reduce the rising prevalence of T2D.",
keywords = "clinical utility, genetic testing, personal utility, Type 2 diabetes",
author = "Allison Vorderstrasse and Alex Cho and Voils, {Corrine I.} and Orlando, {Lori A.} and Ginsburg, {Geoffrey S.}",
year = "2013",
month = "8",
doi = "10.2217/pme.13.47",
language = "English (US)",
volume = "10",
pages = "549--563",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Clinical utility of genetic risk testing in primary care

T2 - The example of Type 2 diabetes

AU - Vorderstrasse, Allison

AU - Cho, Alex

AU - Voils, Corrine I.

AU - Orlando, Lori A.

AU - Ginsburg, Geoffrey S.

PY - 2013/8

Y1 - 2013/8

N2 - Genetic advances in Type 2 diabetes (T2D) have led to the discovery and validation of multiple markers for this complex disease. Despite low predictive value of current T2D markers beyond clinical risk factors and family history, researchers are exploring the clinical utility and outcomes of implementation in practice, and testing is available via direct-to-consumer markets. Clinical utility research demonstrates high hypothetical utility to patients for motivating behavior change and potentially reducing risk. However, trials to date have not demonstrated improvements in behavioral and clinical outcomes over and above counseling based on traditional risk factors. Ongoing research in T2D genetics and associated risk-prediction models is necessary to refine genetic risk pathways, algorithms for risk prediction and use of this information in clinical care. Further research is also needed to explore care models and support interventions that address the needs of personalized risk information and sustainable preventive behaviors to reduce the rising prevalence of T2D.

AB - Genetic advances in Type 2 diabetes (T2D) have led to the discovery and validation of multiple markers for this complex disease. Despite low predictive value of current T2D markers beyond clinical risk factors and family history, researchers are exploring the clinical utility and outcomes of implementation in practice, and testing is available via direct-to-consumer markets. Clinical utility research demonstrates high hypothetical utility to patients for motivating behavior change and potentially reducing risk. However, trials to date have not demonstrated improvements in behavioral and clinical outcomes over and above counseling based on traditional risk factors. Ongoing research in T2D genetics and associated risk-prediction models is necessary to refine genetic risk pathways, algorithms for risk prediction and use of this information in clinical care. Further research is also needed to explore care models and support interventions that address the needs of personalized risk information and sustainable preventive behaviors to reduce the rising prevalence of T2D.

KW - clinical utility

KW - genetic testing

KW - personal utility

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84881416352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881416352&partnerID=8YFLogxK

U2 - 10.2217/pme.13.47

DO - 10.2217/pme.13.47

M3 - Review article

VL - 10

SP - 549

EP - 563

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 6

ER -